BioSpace News Archive

Career Advice

What’s More Important at Work: Better Perks and Benefits or a Higher Salary?

If you’re currently on the job market or considering looking for a new job soon, you’ll want to take stock of your “new employer wish list” and evaluate the things you want from a new job that you consider non-negotiable, important but not necessary, or nice but completely non-essential.

June 27, 2018
·
2 min read
Business

AbbVie and Calico Add Additional $1 Billion to 2014 Age-Related Disease Deal

Nearly four years after first forging a research collaboration, AbbVie and Calico, Google’s life science company, have extended that 10-year pact with another $1 billion pledge to develop therapies associated with age-related diseases, including neurodegeneration and cancer.

June 27, 2018
·
2 min read
·
Alex Keown
Genetown

Summit Crashes in Pre-Market Trading Following Failure of Mid-Stage DMD Treatment

Shares of Summit Therapeutics plunged more than 78 percent in premarket trading.

June 27, 2018
·
2 min read
·
Alex Keown
Deals

Rubius Therapeutics Looks to Raise $200 Million in IPO for Red-Cell Therapies

Three months after securing $100 million in a crossover financing round, Cambridge, Mass.-based Rubius Therapeutics is looking at a $200 million initial public offering to support its personalized red blood cell therapeutics program.

June 27, 2018
·
2 min read
·
Alex Keown
Deloitte Survey Finds Biopharma Companies are Accelerating Adoption of Real-World Evidence

A recent survey shows that 90 percent of biopharma companies are making significant investments in real-world evidence capabilities to support multiple annual objectives that include driving drug development and meeting regulatory requirements.

June 27, 2018
·
4 min read
·
Alex Keown
Drug Development

Merck and AstraZeneca’s Lynparza Positive in Ovarian Cancer Trial

AstraZeneca and Merck announced positive results from their Phase III SOLO-1 clinical trial of Lynparza (olaparib) in BRCA-mutated (BRCAm) advanced ovarian cancer.

June 27, 2018
·
2 min read
·
Mark Terry
FDA

FDA Committee Votes 14 to 3 Against Pain Therapeutics’ Remoxy ER

Pain Therapeutics stock plunged 70 percent after a U.S. Food and Drug Administration (FDA) advisory committee voted 14 to 3 against approval of its Remoxy ER for severe pain.

June 27, 2018
·
2 min read
·
Mark Terry
Drug Development

Despite Being Considered Low Margin, Companies Still Go After Vaccines

The biopharma industry generally views vaccines to be low-margin investments. From a public health perspective, however, vaccines can be one of the best investment dollars.

June 27, 2018
·
5 min read
·
Mark Terry
Deals

Neon Therapeutics to Launch IPO at $16 Per Share

Cambridge, Massachusetts-based Neon Therapeutics is launching an initial public offering (IPO) of 6,250,000 shares of common stock at a price offering of $16 per share.

June 27, 2018
·
2 min read
·
Mark Terry
Business

AbbVie Leads $53 Million Funding Round for startup Carisma Therapeutics

AbbVie Ventures, the investment arm of AbbVie, led a $53 million Series A funding round for Carisma Therapeutics and its immunotherapy CAR-Macrophage platform.

June 27, 2018
·
3 min read
·
Alex Keown